PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
65.75%
Positive net income growth while Drug Manufacturers - Specialty & Generic median is negative at -16.04%. Peter Lynch would view it as a strong advantage vs. struggling peers.
-3.39%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-808.97%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-10.01%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
193.51%
Working capital of 193.51% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
-1178.75%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
18.16%
Inventory growth of 18.16% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
552.49%
AP growth of 552.49% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
559.90%
Growth of 559.90% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
60.13%
Growth of 60.13% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
293.60%
CFO growth of 293.60% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
2.92%
CapEx growth of 2.92% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
10316.78%
Acquisition growth of 10316.78% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
200.00%
Purchases growth of 200.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
16.81%
Proceeds growth of 16.81% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or certain maturities are driving this difference.
265.10%
Growth of 265.10% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
51.11%
Investing flow of 51.11% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
94.19%
Debt repayment growth of 94.19% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.